13 July 2022: Clinical Research
Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland
Iwona Homa-Mlak 1ACDEF* , Marcin Mazurek 1BCEF , Aleksandra Majdan 1DEF , Radosław Mlak 1ACDE , Maria Majdan 2ADEF , Teresa Mełecka-Massalska 1ADEFDOI: 10.12659/MSM.936534
Med Sci Monit 2022; 28:e936534
Table 5 Differences in calprotectin value depending on clinical manifestation of SLE in the study group.
| Variable | Median | p |
|---|---|---|
| Form of disease | 0.3768 | |
| Kidney | 3.05 | |
| Articular | 3.18 | |
| Dermal | 3.08 | |
| Neuropsychiatric | 3.82 | |
| Haematological | 3.16 | |
| Photosensitivity | 0.7673 | |
| Yes | 3.10 | |
| No | 3.10 | |
| Skin changes | 0.7673 | |
| Yes | 3.10 | |
| No | 3.11 | |
| Erosions of the mucous membranes | 0.3572 | |
| Yes | 3.17 | |
| No | 3.10 | |
| Tiredness | 0.3173 | |
| Yes | 3.11 | |
| No | 3.02 | |
| Fever | 0.1618 | |
| Yes | 3.16 | |
| No | 3.06 | |
| Raynaud’s syndrome | 0.4392 | |
| Yes | 3.25 | |
| No | 3.09 | |
| Chair loss | 0.4097 | |
| Yes | 3.22 | |
| No | 3.06 | |
| Myopathy | 0.0277* | |
| Yes | 3.94 | |
| No | 3.09 | |
| Vasculitis | 0.1049 | |
| Yes | 3.25 | |
| No | 3.06 | |
| Arthritis | 0.9454 | |
| Yes | 3.10 | |
| No | 3.10 | |
| Arthralgia | 0.0942 | |
| Yes | 3.12 | |
| No | 3.01 | |
| Pleurisy | 0.1416 | |
| Yes | 3.92 | |
| No | 3.09 | |
| Pericarditis | 0.8921 | |
| Yes | 3.06 | |
| No | 3.11 | |
| Epilepsy | 0.4510 | |
| Yes | 3.47 | |
| No | 3.10 | |
| Seizures | 0.0938 | |
| Yes | 3.94 | |
| No | 3.10 | |
| Psychosis | – | |
| Yes | 3.83 | |
| No | 3.10 | |
| Proteinuria | 0.0711 | |
| Yes | 3.06 | |
| No | 3.21 | |
| Hematuria | 0.4687 | |
| Yes | 3.05 | |
| No | 3.11 | |
| Chronic kidney disease | 0.3191 | |
| Yes | 3.04 | |
| No | 3.11 | |
| Hepatomegaly | 0.3272 | |
| Yes | 3.76 | |
| No | 3.10 | |
| Splenomegaly | 0.2922 | |
| Yes | 3.43 | |
| No | 3.11 | |
| Lymphadenopathy | 0.4022 | |
| Yes | 3.45 | |
| No | 3.10 | |
| * Statistically significant results. | ||